| 3.39 0 (0%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.95 | 1-year : | 4.62 |
| Resists | First : | 3.39 | Second : | 3.95 |
| Pivot price | 3.3  |
|||
| Supports | First : | 3.29 | Second : | 3.23 |
| MAs | MA(5) : | 3.33 |
MA(20) : | 3.28 |
| MA(100) : | 2.94 |
MA(250) : | 2.14 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 90 |
D(3) : | 78.8 |
| RSI | RSI(14): 82.3 | |||
| 52-week | High : | 3.39 | Low : | 1.12 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ THTX ] has closed It is unclear right now based on current values. 55.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 44 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.4 - 3.41 | 3.41 - 3.43 |
| Low: | 3.31 - 3.34 | 3.34 - 3.35 |
| Close: | 3.36 - 3.39 | 3.39 - 3.42 |
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Thu, 25 Sep 2025
$3.01 Per Share Plus $1.19 CVR: Future Pak Completes Acquisition of Biotech Firm Theratechnologies - Stock Titan
Sat, 20 Sep 2025
Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update - MarketBeat
Tue, 16 Sep 2025
Court Approves Biotech Deal: Theratechnologies Gets Final Green Light for Future Pak Acquisition - Stock Titan
Sat, 13 Sep 2025
Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update - MarketBeat
Thu, 03 Jul 2025
Theratechnologies stock soars after $254 million acquisition deal - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 46 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 45.4 (%) |
| Shares Short | 209 (K) |
| Shares Short P.Month | 228 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.62 |
| Profit Margin | -10.9 % |
| Operating Margin | -10.8 % |
| Return on Assets (ttm) | 7.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -19.5 % |
| Gross Profit (p.s.) | 1.42 |
| Sales Per Share | 1.83 |
| EBITDA (p.s.) | 0.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -17.85 |
| PEG Ratio | 0 |
| Price to Book value | -5.56 |
| Price to Sales | 1.84 |
| Price to Cash Flow | 22.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|